BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 23769397)

  • 1. BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease.
    Lim YY; Villemagne VL; Laws SM; Ames D; Pietrzak RH; Ellis KA; Harrington KD; Bourgeat P; Salvado O; Darby D; Snyder PJ; Bush AI; Martins RN; Masters CL; Rowe CC; Nathan PJ; Maruff P;
    Neurobiol Aging; 2013 Nov; 34(11):2457-64. PubMed ID: 23769397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease.
    Lim YY; Villemagne VL; Laws SM; Pietrzak RH; Snyder PJ; Ames D; Ellis KA; Harrington K; Rembach A; Martins RN; Rowe CC; Masters CL; Maruff P
    Mol Psychiatry; 2015 Nov; 20(11):1322-8. PubMed ID: 25288138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BDNF Val66Met in preclinical Alzheimer's disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF.
    Lim YY; Rainey-Smith S; Lim Y; Laws SM; Gupta V; Porter T; Bourgeat P; Ames D; Fowler C; Salvado O; Villemagne VL; Rowe CC; Masters CL; Zhou XF; Martins RN; Maruff P
    Int Psychogeriatr; 2017 Nov; 29(11):1825-1834. PubMed ID: 28720165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of BDNF Val66Met on memory decline and hippocampal atrophy in prodromal Alzheimer's disease: a preliminary study.
    Lim YY; Villemagne VL; Laws SM; Ames D; Pietrzak RH; Ellis KA; Harrington K; Bourgeat P; Bush AI; Martins RN; Masters CL; Rowe CC; Maruff P;
    PLoS One; 2014; 9(1):e86498. PubMed ID: 24475133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction Between BDNF Val66Met and APOE4 on Biomarkers of Alzheimer's Disease and Cognitive Decline.
    Stonnington CM; Velgos SN; Chen Y; Syed S; Huentelman M; Thiyyagura P; Lee W; Richholt R; Caselli RJ; Locke DEC; Lu B; Reiman EM; Su Y; Chen K
    J Alzheimers Dis; 2020; 78(2):721-734. PubMed ID: 33044176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease.
    Lim YY; Hassenstab J; Cruchaga C; Goate A; Fagan AM; Benzinger TL; Maruff P; Snyder PJ; Masters CL; Allegri R; Chhatwal J; Farlow MR; Graff-Radford NR; Laske C; Levin J; McDade E; Ringman JM; Rossor M; Salloway S; Schofield PR; Holtzman DM; Morris JC; Bateman RJ;
    Brain; 2016 Oct; 139(Pt 10):2766-2777. PubMed ID: 27521573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decline in cognitive function over 18 months in healthy older adults with high amyloid-β.
    Ellis KA; Lim YY; Harrington K; Ames D; Bush AI; Darby D; Martins RN; Masters CL; Rowe CC; Savage G; Szoeke C; Villemagne VL; Maruff P;
    J Alzheimers Dis; 2013; 34(4):861-71. PubMed ID: 23302660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain-derived neurotrophic factor polymorphism Val66Met influences cognitive abilities in the elderly.
    Miyajima F; Ollier W; Mayes A; Jackson A; Thacker N; Rabbitt P; Pendleton N; Horan M; Payton A
    Genes Brain Behav; 2008 Jun; 7(4):411-7. PubMed ID: 17973920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hippocampal volume and the brain-derived neurotrophic factor Val66Met polymorphism in first episode psychosis.
    Smith GN; Thornton AE; Lang DJ; Macewan GW; Ehmann TS; Kopala LC; Tee K; Shiau G; Voineskos AN; Kennedy JL; Honer WG
    Schizophr Res; 2012 Feb; 134(2-3):253-9. PubMed ID: 22192502
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Boots EA; Schultz SA; Clark LR; Racine AM; Darst BF; Koscik RL; Carlsson CM; Gallagher CL; Hogan KJ; Bendlin BB; Asthana S; Sager MA; Hermann BP; Christian BT; Dubal DB; Engelman CD; Johnson SC; Okonkwo OC
    Neurology; 2017 May; 88(22):2098-2106. PubMed ID: 28468845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of brain-derived neurotrophic factor Val66Met polymorphism on hippocampal volume change in schizophrenia.
    Koolschijn PC; van Haren NE; Bakker SC; Hoogendoorn ML; Hulshoff Pol HE; Kahn RS
    Hippocampus; 2010 Sep; 20(9):1010-7. PubMed ID: 19714565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers.
    Ho BC; Milev P; O'Leary DS; Librant A; Andreasen NC; Wassink TH
    Arch Gen Psychiatry; 2006 Jul; 63(7):731-40. PubMed ID: 16818862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease.
    Lim YY; Villemagne VL; Pietrzak RH; Ames D; Ellis KA; Harrington K; Snyder PJ; Martins RN; Masters CL; Rowe CC; Maruff P;
    Neurobiol Aging; 2015 Mar; 36(3):1239-44. PubMed ID: 25559335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationships between performance on the Cogstate Brief Battery, neurodegeneration, and Aβ accumulation in cognitively normal older adults and adults with MCI.
    Lim YY; Pietrzak RH; Bourgeat P; Ames D; Ellis KA; Rembach A; Harrington K; Salvado O; Martins RN; Snyder PJ; Masters CL; Rowe CC; Villemagne VL; Maruff P
    Arch Clin Neuropsychol; 2015 Feb; 30(1):49-58. PubMed ID: 25467942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BDNF val66met modulates the association between childhood trauma, cognitive and brain abnormalities in psychoses.
    Aas M; Haukvik UK; Djurovic S; Bergmann Ø; Athanasiu L; Tesli MS; Hellvin T; Steen NE; Agartz I; Lorentzen S; Sundet K; Andreassen OA; Melle I
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():181-8. PubMed ID: 23876786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aβ amyloid, cognition, and APOE genotype in healthy older adults.
    Lim YY; Ellis KA; Ames D; Darby D; Harrington K; Martins RN; Masters CL; Rowe C; Savage G; Szoeke C; Villemagne VL; Maruff P;
    Alzheimers Dement; 2013 Sep; 9(5):538-45. PubMed ID: 23159043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aβ and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ellis KA; Darby D; Ames D; Harrington K; Martins RN; Masters CL; Szoeke C; Savage G; Villemagne VL; Rowe CC;
    Alzheimers Dement; 2014 Nov; 10(6):743-751.e1. PubMed ID: 24589436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cognitive function, serum BDNF levels and BDNF gene Val66Met polymorphism in amnestic mild cognitive impairment].
    Yu H; Zhang ZJ; Shi YM; Bai F; Qian Y; Yuan YG; Deng LL
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Apr; 33(4):321-5. PubMed ID: 18460776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.
    Villemagne VL; Burnham S; Bourgeat P; Brown B; Ellis KA; Salvado O; Szoeke C; Macaulay SL; Martins R; Maruff P; Ames D; Rowe CC; Masters CL;
    Lancet Neurol; 2013 Apr; 12(4):357-67. PubMed ID: 23477989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
    Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.